<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643849</url>
  </required_header>
  <id_info>
    <org_study_id>SRS 1.0</org_study_id>
    <nct_id>NCT02643849</nct_id>
  </id_info>
  <brief_title>Use of The Spanner Temporary Prostatic Stent as an Alternative to a Urinary Catheter to Achieve Bladder Drainage in Men</brief_title>
  <official_title>Use of The SpannerÂ® Temporary Prostatic Stent as an Alternative to a Urinary Catheter to Achieve Bladder Drainage in Men Unfit for Other Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SRS Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SRS Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Spanner is being evaluated for use to manage voiding dysfunction and lower urinary tract
      symptoms in subjects to achieve bladder drainage in men unfit for other treatments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">February 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-void residual (measured in ml of urine) using bladder ultrasound</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Urinary Retention</condition>
  <arm_group>
    <arm_group_label>Spanner</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Spanner Temporary Prostatic Stent</intervention_name>
    <arm_group_label>Spanner</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 45 years;

          -  In urinary retention and catheterized (indwelling or intermittent) for less than 180
             days;

          -  Documented diagnostic history (within 180 days of study) of detrusor contractility (&gt;=
             15 cmH2O) confirmed via pressure-flow test;

          -  Negative Urinalysis on Visit 1;

          -  Not a candidate for pharmacologic, minimally invasive or surgical treatment of the
             prostate;

          -  Charlson Weighted Index of Comorbidity Score &gt;= 1;

          -  Willing and able to sign the Informed Consent Form;

          -  Willing and able to complete the follow-up protocol requirements;

          -  Experiencing catheter-induced discomfort.

        Exclusion Criteria:

          -  Current use of a urinary catheter daily for greater than 180 consecutive days
             immediately preceding entering into the study;

          -  Positive Urinalysis on Visit 1;

          -  Current or recent (within the last 6 months) urinary tract disease including urethral
             stricture, bladder stones, and other significant urological conditions or surgery;

          -  Surgery altering the normal uro-genital anatomy or abnormal urethral anatomy that
             affect the function of the lower urinary tract;

          -  History of conditions associated with neurogenic bladder, including spinal cord
             injury, multiple sclerosis, or Parkinson's disease;

          -  Use of anticholinergic medication;

          -  Gross hematuria when catheter is removed on Visit 1;

          -  Known or suspected prostate cancer;

          -  Prior pelvic irradiation therapy;

          -  Prostatic urethral length &lt; 4 cm or &gt; 9 cm (combined length from the top proximal side
             of the bladder neck to the bottom distal side of the external sphincter);

          -  Intravesical enlargement of the median lobe of the prostate.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Atlantic Urology</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Urology Specialists</name>
      <address>
        <city>Oxford</city>
        <state>Florida</state>
        <zip>34484</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Specialists of West Florida</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinellas Urology Inc</name>
      <address>
        <city>South Pasadena</city>
        <state>Florida</state>
        <zip>33707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Boston Urology</name>
      <address>
        <city>Hingham</city>
        <state>Massachusetts</state>
        <zip>02043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooklyn Urology Research Group</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>December 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Retention</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

